source
- AstraZeneca puts $2 billion into Summit Therapeutics and partners to test ivonescimab with its oncology pipelineAstraZeneca announced a $2 billion equity investment in Summit Therapeutics, acquiring roughly 109,000 shares of convertible preferred stock. The deal will give AstraZeneca about a 12% stake in Sum…
- UniQure’s gene therapy still slows Huntington’s disease after four years, but benefit declinesUniQure reported that its one‑time gene therapy, AMT‑130, continues to decelerate the progression of Huntington’s disease four years after being surgically delivered into patients' brains. A new a…